Why the study?
No therapeutic approaches currently prevent post-MI pathological fibrosis, and trials often fail due to systemic toxicity and lacking delivery systems targeting activated cardiac fibroblasts.
Does CF-targeted delivery of PF543 improve therapeutic efficacy and reduce systemic toxicity compared to systemic administration in a MI mouse model?
Does CF-targeted delivery of PF543 improve therapeutic efficacy and reduce systemic toxicity compared to systemic administration in a MI mouse model?
A novel GSH-responsive nanoparticle platform enables targeted delivery of antifibrotic drugs to cardiac fibroblasts, improving efficacy and reducing toxicity in post-MI mice.
Supports targeted PF543 delivery in mouse MI models; hypothesis-generating and leaves open human translation.
Upon myocardial infarction (MI), activated cardiac fibroblasts (CFs) begin to remodel the myocardium, leading to cardiac fibrosis and even heart failure. No therapeutic approaches are currently available to prevent the development of MI-induced pathological fibrosis. Most pharmacological trials fail from poor local drug activity and side effects caused by systemic toxicity, largely due to the lack of a heart-targeted drug delivery system that is selective for activated CFs. Here, we developed a reduced glutathione (GSH)-responsive nanoparticle platform capable of targeted delivering of drugs to activated CFs within the infarct area of a post-MI heart. Compared with systemic drug administration, CF-targeted delivery of PF543, a sphingosine kinase 1 inhibitor identified in a high-throughput antifibrotic drug screening, had higher therapeutic efficacy and lower systemic toxicity in a MI mouse model. Our results provide a CF-targeted strategy to deliver therapeutic agents for pharmacological intervention of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: